Acadia Pharmaceuticals Inc (ACAD): Glenn Baity , EVP AND GC of Acadia Pharmaceuticals Inc sold 16,000 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $35.00 per share for a total value of $560,032.75 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 4, 2016, Glenn Baity (EVP AND GC) sold 7,000 shares at $20.80 per share price.On Feb 19, 2015, Uli Hacksell (CEO) sold 30,000 shares at $34.30 per share price.
Shares of ACADIA Pharmaceuticals (ACAD) ended Monday, Jul 11, 2016 session in red amid volatile trading. The shares closed down -0.7 points or -2.02% at $33.92 with 13,95,128 shares getting traded. Post opening the session at $34.99, the shares hit an intraday low of $33.87 and an intraday high of $35.18 and the price vacillated in this range throughout the day. The company has a market cap of $3,838 M and the number of outstanding shares has been calculated to be 11,31,63,010 shares. The 52-week high of ACADIA Pharmaceuticals is $51.99 and the 52-week low is $16.64.
Company has been under the radar of several Street Analysts.ACADIA Pharmaceuticals is Downgraded by BofA/Merrill to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jun 22, 2016.ACADIA Pharmaceuticals is Downgraded by Leerink Partners to Mkt Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on May 3, 2016.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis Alzheimers disease psychosis Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan has discovered and engaged in the development of small-molecule product candidates such as alpha adrenergic agonists and muscarinic receptors.